文献速递治疗药物监测与药物基因组学肝肾功能剂量调整特殊人群用药

贝叶斯给药模拟器:优化抗生素治疗的美罗培南药动学建模工具

Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy.
PubMed 文献 · Pharmacotherapy · 2026-01-01

本研究将已发表的美罗培南非参数群体药动学模型转化为参数化贝叶斯框架,并开发为Shiny应用(BDS)。利用18例危重症患者(非CRRT 13例,CRRT 5例)的血浆PK数据进行外部验证,预测准确性(rMPE、rMAPE)与参考模型Pmetrics相当,且在稀疏采样下表现稳健,支持其用于美罗培南个体化给药的可行性。

要点

  • BDS在稀疏采样(1-3个观测点)下预测误差仍控制在预设范围(rMPE ±20%,rMAPE ≤30%)。
  • CRRT患者中模拟群体预测误差较大(rMPE -25%,rMAPE 34%),但贝叶斯更新后可改善。
  • 该工具基于开源框架实现,支持临床实时个体化美罗培南剂量调整。

核心结论

  • 将验证过的非参数美罗培南模型成功植入开源贝叶斯框架,预测精度与参考模型相当,且在稀疏采样下表现稳健。

研究设计与样本

  • 基于已发表的非参数模型转化为参数化贝叶斯框架,通过Shiny界面实现最大后验概率(MAP)更新。
  • 采用18例危重症患者(非CRRT 13例,CRRT 5例)的血浆PK数据进行外部验证。

主要发现

  • 在Pmetrics中,rMPE范围为-7.7%至9.4%,rMAPE范围为18.5%至25.5%(按肾脏替代分层和预测类型)。
  • 模拟群体预测误差较大:CRRT患者rMPE/rMAPE为-25%/34%,非CRRT患者为-21%/30%。
  • BDS各采样场景下预测误差均在预设限内(rMPE ±20%,rMAPE ≤30%),F20为80%至94%,F30为87%至94%。

临床怎么用

  • 临床可利用BDS进行美罗培南个体化剂量优化,尤其适用于CRRT等复杂危重症患者。
  • 稀疏采样(如1-3个血药浓度)即可获得可靠预测,便于临床实施治疗药物监测(TDM)。

局限性

  • 需前瞻性评估其临床安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meropenem is widely used to treat hospital-acquired pneumonia in critically ill patients, with efficacy dependent on the time that free concentrations exceed the minimum inhibitory concentration (fT > MIC). In practice, single-sample therapeutic drug monitoring (TDM) may not ensure target attainment, particularly in patients requiring continuous renal replacement (CRRT). Model-informed precision dosing (MIPD) enables individualized, real-time adjustments, but implementation is limited. Herein, we developed a Shiny application for Bayesian meropenem dose optimization. METHODS: A previously published nonparametric model was translated into a parametric Bayesian framework with maximum a posteriori (MAP) updating implemented through a Shiny interface. Plasma pharmacokinetic (PK) data from critically ill patients served for external validation. Posterior predictions were benchmarked against population and individual (MAP) outputs from Pmetrics 3.09 and population median profiles from 1000 Monte Carlo simulations per patient. Predictive performance was assessed using relative median prediction error (rMPE) and relative median absolute prediction error (rMAPE), for the combined cohort overall and stratified by CRRT status. Sparse sampling scenarios (one, two, and three observations per patient) were also evaluated. RESULTS: Eighteen patients were evaluated (non-CRRT n = 13; CRRT n = 5). In Pmetrics, rMPE ranged from -7.7% to 9.4% and rMAPE from 18.5% to 25.5% across renal replacement strata and prediction types. Simulation-based population predictions yielded greater error, with rMPE/rMAPE of -25%/34% in CRRT patients and -21%/30% in non-CRRT patients. Across Bayesian Dosing Simulator (BDS) sampling scenarios, prediction error remained within prespecified limits (rMPE ±20%, rMAPE ≤ 30%), with F20 ranging from 80% to 94% and F30 from 87% to 94%. CONCLUSION: A validated nonparametric meropenem model was successfully implemented within an open-source Bayesian framework yielding predictive accuracy comparable to the reference model with robust performance under sparse sampling, supporting its feasibility for individualized meropenem dosing. Prospective evaluation of its clinical safety and effectiveness is needed.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Valadez A, Scheetz MH, Neely MN, et al. Bayesian Dosing Simulator (BDS): A Pharmacokinetic Modeling Tool for Optimized Antibiotic Therapy. Pharmacotherapy. 2026. PMID: 42057443. doi:10.1002/phar.70148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。